drug research

Two COVID Drugs Added to China’s Public Health Insurance Scheme

A final list of drugs to be included in China's public health insurance scheme was released on January 18. A total of 111 drugs had been added to the catalogue, and that three drugs had been dropped.

China Accepts Junshi Biosciences’ COVID-19 Drug Application

Junshi Biosciences, a Chinese biopharmaceutical company, announced on January 18 that the country's medical products authorities had accepted a new drug application for Deuremidevir Hydrobromide Tablets (project code: JT001/VV116) for the treatment of COVID-19.

Chinese COVID Pill Azvudine to Open for Online Sales

On the evening of December 13, Fosun Pharma, the exclusive commercial partner of Chinese COVID-19 oral drug Azvudine, confirmed that the pills can soon be prescribed through online medical platforms.

Huawei Cloud’s Pangu Drug Molecule Model Accelerates New Drug Discovery

At the HUAWEI CONNECT 2022, Ken Hu, Rotating and Acting Chairman of Huawei, delivered a keynote titled "Unleash Digital," where he talked about how the company is helping organizations make the most of cloud technology to leapfrog their developments.

Yunnan Baiyao Group Cooperates With Huawei for AI Drug Development

Yunnan Baiyao Group, a Chinese medicine developer and manufacturer, announced on July 25 its signing of the "Comprehensive Cooperation Agreement on Artificial Intelligence Drug R&D," alongside Shenzhen-based tech giant Huawei.

China Drugmaker Plunges After Wanda Director Doubts Covid Treatment Efficacy

The stock price of Yiling Pharmaceutical plunged after Wang Sicong, director of Wanda Group, reposted a video on Weibo that questioned whether the WHO had ever recommended the firm’s drug as Covid-19 treatment.

Triastek Reaps Millions in B+ Round of Financing, Led By Triwise Capital

On Tuesday, Chinese 3D printing pharmaceutical company Triastek announced the completion of several hundred million yuan in a B+ round of financing.

Sinotau Pharmaceutical Group Completes $50 Million D+ Round of Financing with Focus on Radiopharmaceutical R&D

Sinotau Pharmaceutical Group announced in a document on Thursday that it has completed a D+ round of financing worth 320 million yuan ($50.03 million). The funds raised are for clinical R&D of new radioactive drugs.

AI Pharmaceutical Company Galixir Completes Two Financing Rounds, Raising Tens of Millions of Dollars

AI pharmaceutical company Galixir announced on Dec. 29 the completion of its latest two financing rounds, the Series A and Series A+, together worth tens of millions of dollars.

Everything about China's Innovation